In a preclinical scenario from an orthotopic SCLC model with extensive disease, Sakamoto et al. showed that treatment with the Met inhibitor PHA665752 inhibited motility and the invasion of SCLC cells harboring high HGF expression [86]. The gene discussed is HGF; the disease is small cell lung carcinoma.